The Defeat of Surgery in Multimetastatic Colorectal Cancer
In this article
The ORCHESTRA Study — The Quiet Lesson of a Negative Phase 3 Trial
Some studies in oncology validate a new treatment; others refute an existing practice. ORCHESTRA is an important study in the second category. JAMApublished this Dutch, randomized, open-label phase 3 study in its 21 April 2026 issue. It tested a practice that has spread rapidly in clinical care over the past decade: in patients with multiorgan metastatic colorectal cancer (mCRC) who respond to first-line chemotherapy, does aggressive tumor "debulking" added to chemotherapy—reducing tumor burden by more than 80% through surgery + radiotherapy + thermal ablation—actually prolong overall survival? The answer from the randomized trial of 382 patients was clear: No. Median overall survival was 27,5 months in the chemotherapy-alone group and 30,0 months in the debulking group; the adjusted hazard ratio was 0,88 (95% CI: 0,70-1,10; p=0,26). Adverse effects, however, were significantly more frequent in the debulking group (serious adverse events 53% vs 39%, p=0,006). The authors' conclusion was clear: "Tumor debulking should not be considered standard care in patients with multiorgan mCRC."
A Fork in the Decision — What Should Be Done for Which Patient?
Colorectal cancer has a feature that sets it apart from other solid tumors: in limited metastatic disease (oligometastases), local treatments can provide long-term survival—even a cure in some cases. This has been demonstrated repeatedly in clinical oncology research over the last 30 years. For patients with a limited number of liver metastases , surgical resection provides 5-year survival in 20-30% of cases; this is a success that is historically unprecedented in metastatic disease. The EORTC 40983 study (Nordlinger et al., 2008 Lancet) showed that adding perioperative chemotherapy (FOLFOX) to surgery prolonged progression-free survival in resectable liver metastases. The EORTC 40004 study (Ruers et al., 2017 JNCI) showed that ablative treatment (RFA) + chemotherapy prolonged overall survival in limited liver metastases unsuitable for surgery. SABR-COMET (Palma et al., 2019 Lancet) showed that stereotactic ablative radiotherapy in oligometastatic cancers with up to 5 metastases increased life expectancy more than twofold (median OS 28 vs 41 months).
This accumulating evidence created a powerful attraction in clinical practice: "If local treatment works for a few metastases, why not use it for many metastases too? Modern technology (laparoscopic surgery, SBRT, microwave ablation) makes this possible." Throughout the 2010s, aggressive debulking approaches became increasingly common in academic centers even for patients with multiorgan mCRC—that is, even those with metastases in the liver + lungs + ovaries + peritoneum + lymph nodes. Many hospitals began acting on a philosophy of "let us do everything that can be done." But there was no prospective randomized evidencesupporting this approach. The previous evidence was a mixture of retrospective series and selection bias—the patients considered suitable for aggressive treatment already had a better prognosis; "selection," rather than "treatment," might have explained the survival difference.
An Ambitious Hypothesis: A 6-Month Survival Benefit
ORCHESTRA enrolled adults with multiorgan mCRC for whom ≥80% of the tumor burden was expected to be removable by debulking (a combination of surgical resection + radiotherapy + thermal ablation) . The design had two layers:
The ORCHESTRA Study Design — Two Stages
- Stage 1 (induction): All patients received 5-FU + oxaliplatin-based chemotherapy (4 cycles of FOLFOX or 3 cycles of CAPOX, ± bevacizumab). Patients with an objective response or stable disease at assessment after two months were randomized (382 patients in total).
- Stage 2 (randomization, 1:1): Chemotherapy alone group (n=192)—chemotherapy was continued; chemotherapy + maximal tumor debulking group (n=190)—chemotherapy was continued + ≥80% of all metastases were debulked within 3 months (successive surgery, radiotherapy, thermal ablation).
- Primary endpoint: Overall survival—expected to be at least 6 months longer in the debulking group (estimated ~24 months for the control group and ~30 months for the intervention group).
- Secondary endpoints: Progression-free survival, serious adverse events, quality of life.
Patients were carefully selected in the study: only those who responded to treatment and whose general condition could withstand local therapies were randomized. The study therefore selected the most suitable patient group and then delivered the most aggressive treatment that could be performed, whatever it took . The modalities used included liver resection, lung resection, peritoneal cytoreduction, hyperthermic intraperitoneal chemotherapy (HIPEC), radiofrequency and microwave ablation, stereotactic body radiotherapy (SBRT), and external beam radiotherapy.
The Limit of a 10-Year Hypothesis
The study's hypothesis was an overall survival gain of at least 6 months . The actual difference was 2,5 months —not statistically significant (HR 0,88, p=0,26). The study therefore neither crossed the threshold of clinical significance nor achieved statistical significance. Moreover:
Details of the ORCHESTRA Results
- Median progression-free survival: The control group had 10,4 months and the debulking group 10,5 months (HR 0,83; 95% CI 0,67-1,02; p=0,08) — p-value was borderline, but did not reach statistical significance.
- Serious adverse events (Grade ≥3): 101 patients in the debulking group (53%), 74 in the control group (39%); p=0,006. Adding aggressive local treatment therefore significantly increased the frequency of adverse effects.
- Treatment-related death: More frequent in the debulking group than in the control group—the exact figures were provided in the article (JAMA 2026;335:1311-1320 tables).
- Median follow-up: 32,3 months—the results therefore rest on a mature dataset.
What Biology Tells Us
To understand ORCHESTRA's negative result, we must return to the biological distinction between oligometastatic and multiorgan disease. Oligometastases represent an intermediate phase in cancer dissemination with genetically low heterogeneity; in some tumors, micrometastases may not yet have formed, so removing visible metastases can truly reduce the disease. But when disease presents across multiple organs, a biological threshold has been crossed:
Why Does the Oligometastatic vs Multiorgan Distinction Matter?
In multiorgan metastatic disease, generally: Tumor cells have already undergone several independent clonal dissemination events; the invisible pool of micrometastases is large; the sustained effect of chemotherapy over years is the principal mechanism keeping the patient alive. In this setting, removing 80% of the visible metastases is like cutting off the visible tip of the iceberg —the systemic biology remains unchanged, but the patient experiences the adverse effects of surgery/radiotherapy.
This also explains why local treatment works in oligometastatic cases: at that stage, cancer has not yet reached "complete systemic dissemination"; the few visible metastases truly reflect the entire metastatic burden. But with multiorgan spread, the visible metastases are merely the tip of the iceberg. ORCHESTRA confirmed this biological reality with clinical evidence.
For Which Patients Does Local Treatment Remain Standard?
✅ LOCAL TREATMENT REMAINS STANDARD — OLIGOMETASTATIC mCRC
EORTC 40983 (Nordlinger 2008): Perioperative FOLFOX in resectable liver metastases → 5-year DFS benefit. EORTC 40004 (Ruers 2017): RFA + chemotherapy in unresectable limited liver metastases → OS benefit. SABR-COMET (Palma 2019): SBRT in oligometastatic cancers with up to 5 metastases → median OS 28 → 41 months. FFCD 9601, JCOG-0603: The role of perioperative chemotherapy in various resectable mCRC scenarios was confirmed.
❌ LOCAL TREATMENT DID NOT BECOME STANDARD — MULTIORGAN mCRC
ORCHESTRA (Gootjes 2026): Tumor debulking + chemotherapy vs chemotherapy alone in multiorgan mCRC → no OS difference (HR 0,88), significantly more serious adverse events. Important: ORCHESTRA does not question the value of local treatment in oligometastatic mCRC; it only shows that adding aggressive local intervention to chemotherapy in multiorgan spread did not provide benefit.
"Can Be Done" and "Should Be Done" Are Not the Same
The ORCHESTRA study has an uncommon importance in modern oncology practice: negative phase 3 results often have a stronger clinical impact than positive results. Whereas positive results offer new treatment options, negative results remove widely used interventions that do not actually provide benefit—protecting patients from unnecessary toxicity and health systems from unnecessary costs. ORCHESTRA did exactly this:
🩺 ORCHESTRA's Implications for Clinical Practice
- 1. In patients with multiorgan mCRC, the "do everything that can be done" approach is not supported by robust evidence; standard care for these patients is palliative systemic treatment.
- 2. Local treatment (surgery, radiotherapy, ablation) remains standard in oligometastatic disease—a few metastases, most suitable for resection or ablation, and a patient with an appropriate performance status.
- 3. At a multidisciplinary tumor board, the answer to "can it be done?" does not automatically answer "should it be done?" A surgeon, radiation oncologist, and interventional radiologist may say "yes, 80% debulking is technically possible in this patient," while an evidence-based medical oncology perspective may say "but doing this will not provide a net benefit to the patient."
- 4. From the patient's perspective: a potential gain of 2,5 months over 32,3 months of follow-up vs a 14% additional risk of serious adverse events + surgical/RT complications —this balance is unfavorable to intervention for most patients.
- 5. In modern oncology algorithms (NCCN, ESMO, Turkish Society of Oncology), the recommendation for local treatment in multiorgan mCRC was already uncertain; ORCHESTRA turns this uncertainty clearly negative .
The Study's Limitations and Important Nuances
Despite its robust design, ORCHESTRA has several important limitations:
⚠️ ORCHESTRA's Limitations
1. Open-label design—patients and physicians knew the treatment arm; quality-of-life reporting could be biased. 2. A survival gain of 6 months in the target patients was expected; the study was statistically underpowered to detect a smaller benefit (for example, 2-3 months). Because the PFS result (HR 0,83, p=0,08) was borderline, the interpretation "there is a small but real benefit that we failed to detect" cannot be ruled out. 3. A heterogeneous intervention package—some patients received only surgery, some only SBRT, and some HIPEC + surgery; subgroup analyses (for example, patients who underwent only liver resection) may produce different results. 4. Treatment duration —up to 3 months were allowed for debulking; some patients' disease may have progressed during that time, and chemotherapy may have been delayed. 5. Modern targeted treatments were not evaluated —the study was conducted in 2013-2023; during that period, anti-EGFR treatment was not given to RAS-mutant patients, immunotherapy was not used outside MSI-H, and BRAF-mutant combinations (BEACON) were not yet standard. Today's chemotherapy/systemic treatment landscape is different, and ORCHESTRA's "chemotherapy alone" control arm does not represent all of standard care in 2026.
The Ten-Year Journey of a Bold Hypothesis
ORCHESTRA exemplifies a category of research rarely seen in clinical oncology: an academic study without industry support, designed for patient benefit, testing a practice already widespread in clinical care, with a high risk of a negative result—and conducted nonetheless. Such studies are difficult to carry out:
Why Are Studies with Negative Hypotheses Rare?
- There is no industry support. No pharmaceutical company is introducing a new drug; clinical research funding came from nonprofit organizations such as KWF (the Dutch Cancer Foundation) and the Blokker-Verwer Foundation.
- Long follow-up lasting years is required. A study lasting 10 years is almost impossible under modern oncology research funding.
- There is clinical resistance. Surgeons and radiation oncologists already using the "aggressive approach" may be reluctant to enroll patients; the "I already know this works" attitude is common.
- Negative results are difficult to publish. Highly prestigious journals more often publish "innovative positive results"; ORCHESTRA's publication in JAMAwas an achievement from this perspective as well.
⚡ WHY DOES IT MATTER?
Aggressive tumor debulking added to chemotherapy in patients with multiorgan metastatic colorectal cancer—reducing ≥80% of metastases through surgery + RT + ablation—was a practice that spread rapidly over the last decade but lacked prospective randomized evidence. ORCHESTRA—a 10-year Dutch academic study—tested this practice in 382 patients and showed that it did not prolong overall survival and significantly increased adverse effects . This is important negative phase 3 evidence defining the limits of the "do everything that can be done" approach in clinical practice. It also clearly demonstrates how different the clinical decision is between oligometastatic mCRC (local treatment is standard) and multiorgan mCRC (local treatment is not standard).
✅ STRENGTHS
Randomized, prospective, multicenter (28 hospitals), with 10 years of follow-up—a study at the upper level of modern clinical research standards. A clear answer regarding the primary endpoint (overall survival). Meticulous patient selection: only patients responding to treatment and suitable for intervention were randomized—the study tested whether the intervention would work in the "best-case scenario." JAMApublication indicates acceptance by the scientific community. Academic independence (funding by KWF and the Blokker-Verwer Foundation) reduces the risk of conflicts of interest.
⚠️ LIMITATIONS
Open-label design (adverse effect and quality-of-life reporting may be biased). The hypothesis was a 6-month OS benefit; the observed difference of 2,5 months did not reach statistical significance. Because the PFS result (HR 0,83, p=0,08) was borderline, the interpretation "there is a small benefit that we failed to detect" is not completely excluded. A heterogeneous intervention package (combinations of surgery/RT/ablation)—subgroup analyses may produce different results. The study period was 2013-2023; modern targeted treatments (standardization of anti-EGFR + chemotherapy in RAS-mutant colorectal cancer, BEACON for BRAF V600E, pembrolizumab for MSI-H) were not yet fully established then—so the "chemotherapy alone" arm in 2026 may be stronger than ORCHESTRA's "chemotherapy alone" arm.
🩺 IMPLICATIONS FOR CLINICAL PRACTICE
Aggressive tumor debulking added to chemotherapy in patients with multiorgan mCRC is not standard care. Clinical decisions should be made at a multidisciplinary tumor board; "technically possible" does not automatically answer "should it be done?" Local treatment for oligometastatic mCRC (surgical liver resection, SBRT, ablation) remains standard care—the evidence is strong. Local treatment with palliative intent (an obstructive primary tumor, a bleeding metastasis, a painful bone metastasis, symptomatic brain metastasis) falls outside ORCHESTRA and remains indicated in these settings. During patient counseling, the adverse effect burden of the "let us do everything possible" approach should be evaluated within a repeated measurement window of 10-15 months.
❓ FUTURE QUESTIONS
Would the result differ if ORCHESTRA were repeated in the era of modern targeted treatments (anti-EGFR for RAS-wild-type disease, BEACON for BRAF V600E, pembrolizumab for MSI-H)? Which subgroups might still benefit from local treatment (liver and lung metastases only vs peritoneal spread, primary tumor location in the right vs left colon, RAS/BRAF/MSI status)? Would the outcome change with ctDNA-guided selection (for example, trying local treatment in patients who are ctDNA-negative after treatment)? Which local treatment (surgery vs SBRT vs ablation) offers the best survival/morbidity ratio? New phase 3 studies are needed to answer these questions; ORCHESTRA did not answer "which type of local treatment," but rather "a package of all types of local treatment."
Sources
- Gootjes EC, Bakkerus L, Adhin AA, et al. Tumor debulking in combination with chemotherapy in multiorgan metastatic colorectal cancer: the ORCHESTRA randomized clinical trial. JAMA 2026;335(15):1311-1320. doi:10.1001/jama.2026.1929.
- Eng C, Yoshino T. ORCHESTRA hits a sour note for debulking in metastatic colorectal cancer (Editorial). JAMA 2026;335(15):1302-1303. doi:10.1001/jama.2026.1950.
- Gootjes EC, et al. Safety and feasibility of additional tumor debulking to first-line palliative combination chemotherapy for patients with multiorgan metastatic colorectal cancer. The Oncologist 2020;25(10):e1525-e1533. (ORCHESTRA interim safety/feasibility analysis.)
- Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983). The Lancet 2008;371(9617):1007-1016.
- Ruers T, Van Coevorden F, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial (EORTC 40004). Journal of the National Cancer Institute 2017;109(9):djx015.
- Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. The Lancet 2019;393(10185):2051-2058.
- Cremolini C, Antoniotti C, Stein A, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. Journal of Clinical Oncology 2020;38(28):3314-3324.
- Eng C, Yoshino T, Ruiz-Garcia E, et al. Colorectal cancer. The Lancet 2024;404(10449):294-310. (Review of the modern mCRC treatment landscape.)
- Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine 2008;359(17):1757-1765. (The introduction of RAS testing into clinical medicine.)
- Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer (BEACON CRC). The New England Journal of Medicine 2019;381(17):1632-1643.
This article is intended as medical news/information and does not provide individualized treatment guidance. Treatment selection for metastatic colorectal cancer should be made by a multidisciplinary oncology tumor board, considering the patient's clinical condition, performance status, pattern of metastatic spread (oligometastatic vs multiorgan), previous treatment history, RAS/BRAF/MSI molecular profile, and other biomarkers. The ORCHESTRA study results show that aggressive tumor debulking + chemotherapy is not standard care in patients with multiorgan metastatic colorectal cancer; however, the role of local treatment (surgical resection, SBRT, ablation) in oligometastatic patients remains supported by evidence. Indications for local treatment with palliative intent (obstruction, bleeding, painful metastasis, symptomatic brain metastasis) fall outside this study. Editor's note: The article is based on the results of the ORCHESTRA randomized clinical trial published in JAMA 2026;335(15):1311-1320 and the editorial commentary by Eng & Yoshino; EORTC 40983, EORTC 40004, and SABR-COMET were cited for historical context.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.